Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2025 | $42.00 | Overweight | Piper Sandler |
| 7/11/2025 | $65.00 | Outperform | Raymond James |
| 12/3/2024 | $82.00 → $100.00 | Buy | BTIG Research |
| 12/3/2024 | $63.00 → $70.00 | Buy | H.C. Wainwright |
| 11/22/2024 | $79.00 | Outperform | Leerink Partners |
| 10/24/2024 | $69.00 | Buy | UBS |
| 9/6/2024 | $70.00 | Buy | Stifel |
| 5/30/2024 | $47.00 | Sector Perform | Scotiabank |
Piper Sandler initiated coverage of Janux Therapeutics with a rating of Overweight and set a new price target of $42.00
Raymond James initiated coverage of Janux Therapeutics with a rating of Outperform and set a new price target of $65.00
BTIG Research reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $100.00 from $82.00 previously
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
10-Q - Janux Therapeutics, Inc. (0001817713) (Filer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the second half of 2025 First patient dosed in lead collaboration program triggers $10 million milestone payment from Merck $996.0 million in cash, cash equivalents, and short-term investments at end of second quarter 2025 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRA
First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced the dosing of the first patient in its TRACTr collaboration with Merck, known as MSD outside of the United States and Canada. Under the terms of the collaboration that was entered in December 2020, Janux is eligible to receive development and com
PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape
Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica
PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it will host a virtual R&D Day at 1:30 PM PT on Thursday, July 24, 2025. The event will include a presentation from management highlighting product candidates identified from its preclinical pipeline to move into clinical trials. These previously undisclosed preclinical programs utilize Janux's expertise and platform technologies to potentially address significant unmet medical needs.
Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)